We can’t show the full text here under this license. Use the link below to read it at the source.
Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
Impact of Diabetes Medication on Pregnancy Outcomes
AI simplified
Abstract
Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during the periconceptional period was assessed in 3351 pregnancies.
- GLP-1 RA exposure was compared to insulin use in pregnancies of women with pregestational type 2 diabetes.
- The risk ratio for major congenital malformations in the GLP-1 RA group was 0.64, indicating no significant increase compared to insulin.
- The risk ratio for stillbirth was 2.05, suggesting a potential increase, but confidence intervals indicate uncertainty.
- For preterm birth, the risk ratio was 1.09, indicating no significant difference from insulin use.
- The risk ratio for small for gestational age () was 0.86, showing no increased risk compared to insulin.
- Preliminary findings suggest that GLP-1 RA use does not lead to increased risks of adverse pregnancy outcomes compared to insulin.
AI simplified
Key numbers
0.64
Risk Ratio for Major Congenital Malformations
GLP-1 RA vs. insulin
4.4%
Stillbirth Rate
GLP-1 RA vs. insulin
34.6%
Preterm Birth Rate
GLP-1 RA vs. insulin